- Home
- CHCT vs ERAS Comparison
CHCT vs ERAS Comparison
Compare CHCT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCT
- ERAS
- Stock Information
- Founded
- CHCT 2014
- ERAS 2018
- Country
- CHCT United States
- ERAS United States
- Employees
- CHCT N/A
- ERAS N/A
- Industry
- CHCT Real Estate Investment Trusts
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CHCT Real Estate
- ERAS Health Care
- Exchange
- CHCT Nasdaq
- ERAS Nasdaq
- Market Cap
- CHCT 425.5M
- ERAS 439.7M
- IPO Year
- CHCT 2015
- ERAS 2021
- Fundamental
- Price
- CHCT $14.11
- ERAS $2.49
- Analyst Decision
- CHCT Buy
- ERAS Buy
- Analyst Count
- CHCT 2
- ERAS 6
- Target Price
- CHCT $18.00
- ERAS $3.83
- AVG Volume (30 Days)
- CHCT 223.1K
- ERAS 2.4M
- Earning Date
- CHCT 10-28-2025
- ERAS 11-11-2025
- Dividend Yield
- CHCT 13.44%
- ERAS N/A
- EPS Growth
- CHCT N/A
- ERAS N/A
- EPS
- CHCT N/A
- ERAS N/A
- Revenue
- CHCT $118,100,000.00
- ERAS N/A
- Revenue This Year
- CHCT $6.73
- ERAS N/A
- Revenue Next Year
- CHCT $6.07
- ERAS N/A
- P/E Ratio
- CHCT N/A
- ERAS N/A
- Revenue Growth
- CHCT 2.96
- ERAS N/A
- 52 Week Low
- CHCT $13.23
- ERAS $1.01
- 52 Week High
- CHCT $20.87
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- CHCT 39.39
- ERAS 67.90
- Support Level
- CHCT $13.23
- ERAS $2.28
- Resistance Level
- CHCT $15.48
- ERAS $2.76
- Average True Range (ATR)
- CHCT 0.34
- ERAS 0.23
- MACD
- CHCT -0.09
- ERAS 0.01
- Stochastic Oscillator
- CHCT 37.33
- ERAS 72.39
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.